SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,261 | -47.5% | 155,714 | -24.3% | 0.02% | -37.1% |
| Q2 2023 | $4,306 | +229.5% | 205,718 | +232.5% | 0.04% | +218.2% |
| Q1 2023 | $1,307 | -99.9% | 61,873 | +5.8% | 0.01% | -38.9% |
| Q3 2022 | $1,405,000 | +21.0% | 58,466 | -3.1% | 0.02% | +28.6% |
| Q2 2022 | $1,161,000 | +239.5% | 60,357 | +206.8% | 0.01% | +250.0% |
| Q1 2022 | $342,000 | +47.4% | 19,673 | +89.9% | 0.00% | +33.3% |
| Q1 2021 | $232,000 | – | 10,359 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |